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1. Introduction 
Chagas  disease,  caused  by  the  protozoan  parasite 
Trypanosoma  cruzi,  is  a  major  neglected  parasitic  disease 
endemic  in  South  and  Central  America  with  an  increasing 
number of cases reported in countries such as USA, Spain and 
Japan.
1,2  Research  into  new  therapies  to  treat  Chagas  disease 
must overcome a number of difficulties arising from the complex 
nature of the parasite's life cycle
3 and its extensive impact on the 
body.
4  Following infection  with  T.  cruzi parasites,  blood-
form trypomastigotes  enter  cells  and  rapidly  proliferate  in 
amastigote  form,  causing  acute  illness  with  mild  symptoms 
lasting for a few weeks. Treatment is effective at this point in 60-
85% of cases,
5 but acute infection can also cause mortality in a 
small number of patients.
6 Parasites remain in the body as the 
disease progresses to an asymptomatic phase during which time 
patients may not be aware they are carriers of the parasite and 
may  never  develop  the  chronic  form  of  the  disease.  Chronic 
Chagas disease can take as long as 15-20 years to present, during 
which  time  the  amastigote  form  of  T.  cruzi  has  caused 
considerable damage to the heart and/or gastrointestinal tract via 
infiltration of soft tissues and stimulation of immune responses.
7 
A  recent  epidemiological  study  of  mortality  related  to  Chagas 
disease in Brazil between 1999–2007 reported 97% of diagnosed 
Chagas  related  deaths  were  due  to  the  chronic  form  of  the 
disease.
6 T. cruzi is genetically highly diverse and is divided into 
six  discrete  typing  units  (DTUs)
8    which  have  the  potential  to 
vary in susceptibility to drug treatment. The current standard of 
care, benznidazole, is given at a high dose for 30-60 days, has 
undesirable side effects leading to poor patient compliance and 
has a limited and controversial impact  against chronic Chagas 
disease.
5 The protracted nature of the illness, extent of parasite 
distribution into the body, monitoring of disease progression and 
determination of cure add complexity to clinical  evaluation of 
existing and promising new treatments.
1,5 
CYP51 is a well-validated drug target for the inhibition of T. 
cruzi and a major drug target in the cytochrome P450 family.
9 
The  enzyme  is  an  important  part  of  sterol  biosynthesis  in 
eukaryotes,  with  inhibition  causing  a  breakdown  in  membrane 
structural  integrity,  fluidity  and  permeability  leading  to 
deleterious down-stream effects.
10 Pioneering work by Urbina et 
al.  brought  antifungal  CYP51  inhibitors  to  the  forefront  of  T. 
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cruzi drug discovery establishing the cross-reactivity of leading 
azole antifungal sterol biosynthesis inhibitors against T. cruzi in 
vitro and in vivo.
11-14 More active second generation antifungals 
posaconazole  and  a  ravuconazole  pro-drug  are  the  first 
compounds  to  enter  clinical  trials  for  the  treatment  of  Chagas 
disease  in  more  than  40  years.  Other  compounds  targeting  T. 
cruzi  CYP51  include  the  tipifarnib  series,
15-18  dialkyl 
imidazoles,
19 LP10,
20 and indomethacin amides,
21 with current hit 
generation  efforts  potentially  fueling  further  research.
22  The 
recently reported crystal structure of T. cruzi CYP51 with bound 
posaconazole and fluconazole is an important step forward in the 
ongoing  story  of  this  target  opening  up  the  opportunity  for 
structure based drug design to address potential issues of drug 
resistance.
23,24 
We  recently  identified  fenarimol  (1),  a  fungicide  used  in 
agriculture  since  the  mid-1970s,  as  having  moderate  in  vitro 
activity against T. cruzi (IC50 350nM) following a targeted hit 
generation campaign
25 utilizing a phenotypic whole organism in 
vitro screen.
26 Fenarimol inhibits fungal CYP51 and is classified 
within  the  pyrimidine  sub-class  of  fungal  CYP51  inhibitors.
27 
The  ability  of  1  to  kill  T.  cruzi  could  occur  by  a  similar 
mechanism  and  the  outcome  of  mechanistic  studies  will  be 
reported  in  due  course.  Structure-activity  relationship  (SAR) 
studies focused on improving potency and establishing  in vivo 
efficacy arrived at optimised triaryl analogue 2, which was orally 
active  in  a  stringent  in  vivo  mouse  model  of  acute  T.  cruzi 
infection. In a general effort to expand the chemical diversity of 
the  fenarimol  series  and  assess  the  subsequent  impact  of  a 
scaffold  hop  on  activity,  selectivity  over  CYP3A4,  solubility, 
oral exposure and ultimately in vivo efficacy, one aromatic ring 
of  the  triaryl  pharmacophore  of  1  and  2  was  replaced  with 
piperazine to give a new 1-(diarylmethyl)piperazinyl scaffold (3) 
which could be further derivatised on the piperazine N-4 atom 
(Figure 1). 
<Insert Fig. 1 here> 
2. Materials and Methods 
2.1. Chemistry 
The retro synthesis of scaffold  3 is illustrated in scheme 1. 
Benzophenones (8) were selected as convenient precursors due to 
their  ease  of  synthesis  from  classical  Friedel-Craft  reactions, 
palladium catalysed acylations or addition of aryl organometallic 
reagents  to  Weinreb  amide  derivatives  of  carboxylic  acids.
25 
Straightforward  reduction  with  sodium  borohydride  gave 
diarylmethanols (6) which were also prepared directly in gram 
quantities by addition of aryl Grignard or aryllithium species to 
aromatic aldehydes at low temperature. As both aromatic groups 
could  be  introduced  as  either  the  organometallic  or  aldehyde 
entity,  the  choice  of  reacting  partners  was  determined  by 
availability  of  reagents  and  reactivity  of  pendent  substituents. 
Conversion  of  6  to  the  corresponding  chloro  derivative  7  on 
reaction with thionyl chloride was followed by substitution with 
t-butyl piperazine-1-carboxylate to give BOC-protected scaffold-
4.  Simple  acid  mediated  deprotection  gave  5  in  overall  good 
yields.  
<Insert Scheme 1 here> 
Reaction  of  5  with  acid  chlorides  gave  piperazinyl-amide 
analogues  13-27;  with  sulfonyl  chlorides  gave  piperazinyl-
sulfonamide  analogues  28-42;  isocyanates  gave  piperazinyl-
carbamates 44, 45, 47, 48, 51, 53-56 and chloroformates gave 
piperazinyl-carbonates 43, 46, 49, 50 and 52. Chloro intermediate 
7 was also reacted with pre-functionalised piperazine analogues 
to give the desired target analogues of 3 directly and to prepare 
R
1 = aryl analogues 57-66.  As representative examples of the 
synthetic methodology, schemes 2 and 3 show the preparation of 
[4-chlorophenyl(pyridin-3-yl)methyl]piperazine  analogues  24, 
29,  46-47  and  62,  respectively.  Compounds  were  prepared  in 
racemic form and synthetic transformations are unoptimised. 
<Insert Scheme 2 here> 
<Insert Scheme 3 here> 
2.2. Biological evaluation 
The  new  [phenyl(pyridin-3-yl)methyl]piperazinyl  derivatives 
13-66 were tested for their ability to inhibit T. cruzi in vitro in a 
whole  parasite  assay.  Specifically,  compounds  were  incubated 
with T. cruzi Tulahuen strain TcVI (a strain transfected with the 
-galactosidase  gene).
26  Parasites  in  the  extra  cellular 
trypomastigote form were added to the plate wells seeded with 
L6 cells (rat skeletal myoblasts) and incubated for 48h to allow 
infection to establish before addition of test compounds and a 
further 4-day incubation period, exposing compounds to both the 
extracellular trypomastigote and intracellular amastigote forms of 
the parasite. An IC50 value was recorded corresponding to the 
concentration of compound required to inhibit 50% of parasite 
growth. Compound cytotoxicity was evaluated in L6-cells as a 
counter-screen. The compounds in this series were determined to 
be  non-cytotoxic  with  selectivity  ratios  for  T.  cruzi:cytoxicity 
generally >100. 
Compounds with good activity or those of structural interest 
were further evaluated for their propensity to undergo  in vitro 
oxidative  metabolism  by  hepatic  microsomes  and  to  inhibit 
CYP3A4,  a  key  drug  metabolising  enzyme  inhibited  by  most 
azole-derived CYP51 antifungals. Solubility in phosphate buffer 
at pH6.5 was also determined. 
Suitable compounds with low to moderate predicted hepatic 
extraction  ratios  (Eh)  were  further  evaluated  in  vivo  by 
measurement of the oral exposure in non-infected Swiss outbred 
mice and subsequently, for in vivo efficacy in a mouse model of 
acute T. cruzi infection.
25 
3. Results and discussion 
The  exploration  of  the  SAR  was  greatly  facilitated  by  the 
tractable synthesis of the target compounds allowing each region 
of the pharmacophore to be investigated independently (Figure 
2). 
<insert Figure 2 here> 
3.1. Structure-activity relationship (SAR) 
Exploration  of  the  heterocycle  and  aromatic  ring  R
2  was 
guided  by  the  results  of  previous  SAR  studies  on  the  triaryl 
series,  which  had  established  3-pyridyl  and  a  handful  of  4-
substituted  phenyl  motifs  as  optimal  for  activity  and  in  vitro 
oxidative  metabolic  stability  (and  thus  oral  exposure).
25  5-
Pyrimidinyl analogues of several compounds were made in this 
study in order to confirm that SAR trends remained true in the 
new piperazine series. The bulk of the SAR exploration was thus 
focused on establishing the best R
1 group. 
In general, across all variations of R
1, the in vitro activity of 
the  new  piperazinyl  compounds  was  very  encouraging  with 
activities  in  the  low  nM  range.  Tables  1-4  show  selected 
analogues from the amide series (Table 1), sulfonamide series   
(Table 2), carbamate/carbonate series (Table 3) and aryl series 
(Table 4). The compounds are ordered by in vitro activity starting 
with the most active analogue and a 2-fold difference in IC50 
value was considered to reflect an actual difference in potency. 
Activity  data  for  reference  compounds  posaconazole  and 
benznidazole has been included in table 1. Posaconazole is very  
active  in  vitro,  in  contrast  to  the  M  activity  level  of 
benznidazole. 
Considering each different R
1 in turn, for R
1 equal to amide 
(Table 1) bulky alkyl amido analogues 13-18 were more potent 
than benzamides 20 and 21. Thiazole 19 showed good activity. 
Pyrimidinyl analogues were less potent than the corresponding 
pyridyl  compounds  (e.g.  15  cf  23)  and  there  was  a  slight 
preference  for  2-F  containing  R
2  analogues  (B  and  D)  and  a 
definite mismatch with R
2 = 4-benzonitrile (E).  
Table 1. R
1 = alkyl and aryl amide (COR
3) 
Cmpd
  aHET
  bR
2  R
3  cTcIC50 M
  dL6IC50 M 
13  3-pyr  B  tBu  0.019  60 
14  3-pyr  D  tBu  0.024  73 
15  3-pyr  B  cPr  0.026  >100 
16  3-pyr  B  cHex  0.028  62 
17  3-pyr  C  tBu  0.030  59 
18  3-pyr  F  iPr  0.035  >100 
19  3-pyr  B  Het
e  0.036  93 
20  3-pyr  A  Ph  0.068  61 
21  3-pyr  B  Ph  0.070  69 
22  5-pyrim  B  tBu  0.081  >100 
23  5-pyrim  B  cPr  0.171  >100 
24  3-pyr  A  Me  0.240  >100 
25  3-pyr  E  tBu  0.254  >100 
26  3-pyr  E  cPr  0.281  >100 
27  3-pyr  E  Het
e  0.513  >100
 
fPosa        0.0007  >100
 
gBnz        1.15  >100
 
aHET: 3-pyr  (3-pyridine), 5-pyrim (5-pyrimidine); 
bA (4-chlorophenyl), B (4-
chloro-2-fluorophenyl), C (4-trifluoromethylphenyl), D (2-fluoro-4-
trifluoromethylphenyl), E (4-benzonitrile), F (4-ipropoxyphenyl). 
cTc = T. 
cruzi, values are the mean of at least two experiments; 
dL6 cells (rat 
myoblasts from skeletal muscle) for assessment of cytotoxicity; 
e19, 27 Het = 
2-(4-methyl-1,3-thiazole); 
f Posa (posaconazole); 
gBnz (benznidazole). 
In  contrast,  the  sulfonamide  series  (Table  2)  showed  a 
preference  for  aryl  sulfonamides  over  alkyl  analogues,  and 
simple  benzenesulfonamides  28  and  29  were  very  active. 
Additional Cl or iPr substituents did not enhance activity. Methyl 
sulfonamides 34, 35 and 37-42 provided an interesting sub-set of 
analogues  with  surprisingly  active  and  equipotent  pyridyl  and 
pyrimidinyl  lead  compounds,  and  a  clear  preference  for  2-F 
containing R
2 analogues B and D (34 cf 41 and 35 cf 38). Similar 
to  the  sulfonamide  set,  aromatic  carbamates  and  carbonates 
(Table 3) were potent and more active than even bulky, lipophilic 
t-butyl  analogues  and  pyridyl  and  pyrimidinyl  analogues  were 
equipotent. No activity advantage of carbamate-NH vs carbonate-
O or for 2-F containing R
2 analogues was evident within the most 
potent aryl derivatives 43-48. 
The R
1 equal to aryl (Table 4) series shared an activity level 
similar to the amide series. The set was very limited in scope, but 
quite electronically diverse analogues such as 57, 58 and 60 were 
essentially  equiactive  suggestive  of  a  flat  SAR  and  thus  non-
optimal  binding  interactions.  This  can  be  understood  by 
considering  that  the  most  active 
sulphonamide/carbonate/carbamate series have an aromatic ring 
extended into chemical space whereas the directly linked N-aryl 
analogues are shorter and linear and probably do not reach into 
the same binding pocket. 
Table 2. R
1 = alkyl and aryl sulfonamide (SO2R
4) 
Cmpd
  aHET
  bR
2  R
4  cTcIC50 M
  dL6IC50 M 
28  3-pyr  B  Ph  0.008  42 
29  3-pyr  A  Ph  0.009  43 
30  3-pyr  A  cHex  0.010  56 
31  3-pyr  A  Ph(4-iPr)  0.012  80 
32  5-pyrim  B  Ph(4-iPr)  0.018  >100 
33  3-pyr  A  Ph(4-Cl)  0.024  23 
34  5-pyrim  D  Me  0.025  >100 
35  3-pyr  D  Me  0.028  77 
36  3-pyr  A  iPr  0.028  >100 
37  3-pyr  B  Me  0.035  >100 
38  3-pyr  C  Me  0.077  >100 
39  3-pyr  A  Me  0.110  >100 
40  3-pyr  E  Me  0.365  >100 
41  5-pyrim  C  Me  0.769  >100 
42  5-pyrim  A  Me  0.880  >100
 
aHET: 3-pyr  (3-pyridine), 5-pyrim (5-pyrimidine); 
bA (4-chlorophenyl), B (4-
chloro-2-fluorophenyl), C (4-trifluoromethylphenyl), D (2-fluoro-4-
trifluoromethylphenyl), E (4-benzonitrile), F (4-ipropoxyphenyl). 
cTc = T. 
cruzi, values are the mean of at least two experiments; 
dL6 cells (rat 
myoblasts from skeletal muscle) for assessment of cytotoxicity. 
Table 3. R
1 = alkyl and aryl carbonates/carbamates (COXR
5 
X=O/NH) 
Cmpd
  aHET
  bR
2  R
5  cTcIC50 M
  dL6IC50 M 
43  3-pyr  B  OPh  0.005  59 
44  5-pyr  B  NHPh  0.006  45 
45  5-pyrim  B  NHPh(4-iPr)  0.007  62 
46  3-pyr  A  OPh  0.008  56 
47  3-pyr  A  NHPh  0.009  67 
48  5-pyrim  B  NHPh(4-Cl)  0.010  34 
49  3-pyr  C  OtBu  0.017  56 
50  3-pyr  B  OtBu  0.020  43 
51  5-pyrim  A  NHPh(4-Cl)  0.022  59 
52  5-pyrim  B  OtBu  0.024  64 
53  5-pyrim  B  NHtBu  0.054  >100 
54  3-pyr  A  NMe2  0.120  >100 
55  5-pyrim  C  NHcPr  >1  >100 
56  3-pyr  E  NHcPr  >1  >100
 
aHET: 3-pyr  (3-pyridine), 5-pyrim (5-pyrimidine); 
bA (4-chlorophenyl), B (4-
chloro-2-fluorophenyl), C (4-trifluoromethylphenyl), D (2-fluoro-4-
trifluoromethylphenyl), E (4-benzonitrile), F (4-ipropoxyphenyl). 
cTc = T. 
cruzi, values are the mean of at least two experiments; 
dL6 cells (rat 
myoblasts from skeletal muscle) for assessment of cytotoxicity. 
   
Table 4. R
1 = aryl (Ar) 
Cmpd
  aHET
  bR
2  Ar
  cTcIC50 
 M
 
dL6IC50 
 M 
57  3-pyr  D  Het
e  0.017  51 
58  3-pyr  B  Ph  0.018  58 
59  3-pyr  A  Ph(2-OMe)  0.020  61 
60  3-pyr  B  2-pyrimidine  0.026  59 
61  3-pyr  F  Ph(2-OMe)  0.028  77 
62  3-pyr  A  Ph  0.034  67 
63  5-pyr  E  2-thiazole  0.050  >100 
64  5-pyrim  B  Ph(2-OMe)  0.065  60 
65  5-pyrim  B  Ph  0.078  63 
66  2-pyra  C  Ph(2-OMe)  0.240  62
 
aHET: 3-pyr  (3-pyridine), 5-pyrim (5-pyrimidine), 2-pyra (2-pyrazine); 
bA 
(4-chlorophenyl), B (4-chloro-2-fluorophenyl), C (4-trifluoromethylphenyl), 
D (2-fluoro-4-trifluoromethylphenyl), E (4-benzonitrile), F (4-
ipropoxyphenyl).  
cTc = T. cruzi, values are the mean of at least two 
experiments; 
dL6 cells (rat myoblasts from skeletal muscle) for assessment of 
cytotoxicity; 
e57 Het = 5-(3-methyl-1,2,4-oxadiazole). 
3.2. Assessment of in vitro ADME and CYP3A4 inhibition 
profiles 
Alongside  the  assessment  of  activity,  compounds  were 
screened  in  vitro  for  oxidative  stability  in  human  liver 
microsomes (to assess the likelihood of rapid hepatic clearance 
limiting systemic exposure after oral administration), solubility at 
pH  6.5  in  phosphate  buffer  and  selectivity  for  T.  cruzi  over 
CYP3A4 (a potentially limiting characteristic of the azole series 
and important for minimising potential drug-drug interactions for 
combination  therapy).
28  Results  for  selected  compounds  are 
shown in Table 5.  
Table 5. Representative in vitro metabolism, solubility and 
CYP selectivity data 
Cmpd  EH
a  Sol.
b   CYP
c   Cmpd  EH
a  Sol.
b  CYP
c 
24  <0.2  >100  7.4  28  0.71  <1.6  0.6 
15  0.59  50-100  1.8  35  0.74  25-50  1 
22  0.63  25-50  7  36  0.76  12.5-25  0.81 
19  0.65  50-100  2.8  29  0.79  <1.6  1.9 
14  0.66  12.5-25  3.9  34  0.84  25-50  5.6 
17  0.68  12.5-25  2.3  48  0.56  3.1-6.3  0.3 
13  0.73  12.5-25  1  53  0.69  50-100  6.9 
16  0.89  6.3-12.5  3.9  50  0.75  3.1-6.3  1.9 
39  0.53  12.5-25  3.6  52  0.76  12.5-25  2.9 
37  0.65  12.5-25  1.3  66  0.9  3.1-6.3  25
 
aMicrosome predicted hepatic extraction ratio (EH) calculated from in vitro 
data in human liver microsomes; 
bkinetic solubility at pH 6.5 in phosphate 
buffer (g/mL) determined by nephelometry;  
cIC50 (M) for the inhibition 
of testosterone-β-hydroxylation by CYP3A4. 
As  is  often  the  case,  the  most  active  compounds  do  not 
necessarily  possess  the  best  “drug-like”  properties.  From  the 
amide series, methyl analogue 24 (T. cruzi IC50 240 nM) was 
very stable to oxidation by microsomes, had excellent solubility 
and only moderate activity at CYP3A4. Higher alkyl and more 
active analogues 15, 19, 14 and 17 (T. cruzi IC50 <40 nM) had 
acceptable profiles. The very active benzenesulfonyl analogues 
28 and 29 (T. cruzi IC50 <10 nM) had disappointing profiles with 
Eh > 0.7 suggesting they would have poor exposure profiles in 
vivo.  Carbamates/carbonates  48,  53,  50  and  52  had  mixed 
profiles with no clear standout compounds, whilst compounds in 
the aryl series were highly metabolised and poorly soluble (data 
not shown). Pyrazinyl analogue 66 had minimal cross-reactivity 
with CYP3A4, but was 10-fold less active than leading pyridyl 
compounds and thus of no real interest. Not enough comparative 
data was collected to determine the influence of R
2 on in vitro 
ADME  and  physicochemical  properties,  but  previous  studies 
with  the  triaryl  series  showed  that  the  rate  of  oxidative 
metabolism  could  be  reduced  by  the  inclusion  of  4-
trifluoromethylphenyl.
25 
3.3. Evaluation of oral exposure  
The  systemic  exposures  of  24  and  37  (citrate  salt)  were 
determined in non-infected male Swiss outbred mice after single 
oral doses of 20, 50 and 100 mg/kg administered by gavage. Both 
compounds exhibited rapid absorption after oral administration, 
with  maximum  concentrations  attained  approximately  15  min 
post-dose. No adverse reactions or compound-related side effects 
were observed following oral administration of either compound 
at the dose levels examined. The apparent half-lives of 37 (T1/2 = 
2.1-2.9 h) and 24 (T1/2 =1.7 – 2.7 h) were similar, however the 
AUC for 37 over the 7.5 h post-dose sampling period was higher 
than that for 24 at each comparable dose (37: AUC0-7.5h (M.h) 
7.2 at 20 mg/kg, 60.2 at 50 mg/kg and 43.7 at 100 mg/kg. 24: 
AUC0-7.5h (M.h) 2.3 at 20 mg/kg, 6.2 at 50 mg/kg and 9.4 at 100 
mg/kg)  (See  supplementary  information  for  oral  exposure 
profiles).  Full-scan  LC-MS  data  were  collected  for  selected 
plasma  samples  to  identify  potential  metabolites.  Putative 
products of oxygenation and amide hydrolysis were detected for 
24,  and  products  of  oxygenation  and  N-dealkylation  were 
observed for 37. Potential metabolites having molecular weights 
consistent  with  the  products  of  glucuronidation,  sulphation  or 
oxygenation followed by conjugation or ring opening were not 
detected. 
3.4. Evaluation of in vivo efficacy 
Compounds 24 and 37 were evaluated for in vivo efficacy in a 
mouse model of acute T. cruzi infection following doses of 20, 
50  and  100  mg/kg.  Female  Swiss  mice  (n=5  per  group)  were 
infected  with  25,000  blood  form  trypomastigotes  of  T.  cruzi 
(Tulahuen strain/Tc VI). Compound dosing commenced on day 8 
post infection (p.i.) and each mouse received the indicated dosage 
of  compound  in  a  single,  once  daily  administration  by  oral 
gavage for 5 consecutive days. Blood parasitemia was evaluated 
on  days  8,  9,  12  and  14  p.i.  and  expressed  as  „number  of 
trypomastigotes/mL of blood‟. Compound efficacy was indicated 
by  a  decrease  in  parasitemia  levels  in  comparison  to  vehicle-
treated  mice  on  day  14  p.i..  Posaconazole  (Noxafil®)  treated 
mice  (50  and  100  mg/kg)  were  used  as  a  positive  control 
alongside the vehicle only treated group. 
<insert Figure 3 here> 
Compared  to  vehicle-treated  mice,  24  was  unable  to 
significantly  reduce  blood  parasitemia  at  all  doses  tested  (Fig. 
3A)  but  was  able  to  improve  survival.  All  24-treated  mice 
survived to the end of the treatment period (day 14) whereas 60% 
of vehicle-treated mice did not survive past day 12 (Fig. 4A). In 
contrast, 37-treated mice had significantly improved reduction in 
parasitemia when dosed at 100, 50 and 20 mg/kg (96%, 95% and 
73%) compared to vehicle-treated on day 14, respectively) (Fig. 
3B).  All  37-treated  mice  had  improved  survival  outcomes   
relative to vehicle (4/5 mice at 20mg/kg; 5/5 at 50mg/kg and 4/5 
at 100 mg/kg survived to the end of the experiment) (Fig. 4B). 
This was comparable to the positive control, posaconazole, which 
reduced blood parasitemia to below detectable limits by day 14 
p.i. in both 50 mg/kg and 100 mg/kg treated groups (Fig. 3C), 
with 3/5 mice (50 mg/kg) and 4/5 mice (100 mg/kg) surviving to 
the end of the experiment (Fig. 4). 
<insert Figure 4 here> 
4. Conclusions 
Simple  1-[phenyl(pyridin-3-yl)methyl]piperazinyl  analogues 
of fenarimol were investigated for their ability to inhibit T. cruzi 
in vitro in a whole parasite assay and further studied for in vivo 
efficacy in a mouse model of acute T. cruzi infection. A range of 
analogues bearing amide, sulfonamide, carbamate/carbonate and 
aryl  substituents  appended  to  [phenyl(pyridin-3-
yl)methyl]piperazine scaffolds 3 exhibited low nM activities in 
vitro. Two compounds, 24 and 37, gave good plasma exposures 
in mice following oral administration and were tested for efficacy 
in  vivo.  Compound  37  was  able  to  significantly  reduce 
parasitemia in a mouse model of acute  T. cruzi infection after 
once  daily  oral  dosing  at  20,  50  and  100  mg/kg  for  5  days, 
consistent  with  a  higher  potency  and  overall  superior  plasma 
concentration profile compared to 24 which was not efficacious 
in  vivo.  The  tractable  synthesis  of  the  target  compounds,  oral 
exposure profiles and demonstrated in vivo efficacy of 37 makes 
the 1-[phenyl(pyridin-3-yl)methyl]piperazinyl series an attractive 
target for further optimisation. 
 
5. Experimental 
5.1.  General.  Reagents  were  purchased  from  commercial 
suppliers  and  used  without  further  purification.  Commercially 
available  anhydrous  solvents  were  used  and  stored  under 
nitrogen,  unless  indicated  otherwise.  Reactions  involving 
moisture sensitive reagents were conducted under an atmosphere 
of dry nitrogen in glassware dried with a heat-gun. Thin layer 
chromatography (TLC) using silica gel Merck 60 F254 plates and 
detection with UV light was used to monitor reactions. 
1H NMR 
spectra were recorded in CDCl3, CD3OD or DMSO-d6 solutions 
on  a  Varian  200,  Brucker  300  or  Varian  400MHz  machine. 
Chemical shifts are reported in parts per million (δ) downfield of 
tetramethylsilane (TMS). GC-MS were acquired on an Agilent 
5973  network  machine.  LC-MS  were  acquired  on  an  Applied 
Biosystems  /  MDS  Sciex  API-2000  system.  Flash 
chromatography  was  carried  out  with  silica  gel  (0.04-0.06μm, 
230-400 mesh), reverse phase silica gel (C18 35-70μm) or on a 
Flashmaster  II  system  using  cartridges  prepared  in-house. 
Microwave irradiations were conducted using a Biotage initiator. 
All  compounds  tested  in  the  in  vitro  and  in  vivo  biological 
screens were purified to >95% purity as determined by analysis 
of HPLC on an Agilent 1100 series machine, fitted with a C8 
reverse phase Agilent zorbax eclipse DB-LB 4.6 x 150 mm 5μm 
column  (flow  rate  1.2mL/min;  method  1:  20%  acetonitrile  in 
water, increasing to 60% acetonitrile over 10min; method 2: 50% 
acetonitrile in water increasing to 90% acetonitrile over 10min; 
method  3:  70%  acetonitrile  in  water  increasing  to  95% 
acetonitrile over 10min); 
1H NMR spectra (accounting for non-
compound peaks and residual solvent) and in some cases LC-MS 
or  GC-MS.  Fenarimol  [60168-88-9]  (1)  was  purchased  from 
commercial  sources  and  posaconazole  was  a  gift  from  the 
CDCO. 
5.2. Synthesis of compounds. 
 The  preparation  of  [4-chlorophenyl(pyridin-3-
yl)methyl]piperazine analogues 24, 29, 46, 47 and 62 is provided 
as a representative example of the synthetic methodology. The 
synthesis of compound 37 is also described. Methods and data 
for other reported compounds is available in the supplementary 
material. 
Preparation  of  diarylmethanol  intermediates  (6)  from 
benzophenones.
25 
(4-Chlorophenyl)(pyridin-3-yl)methanol (9).  To a solution 
of  3-(4-chlorobenzoyl)pyridine  (3g,  14mmol)  in  methanol 
(20mL) was slowly added sodium borohydride (0.72g, 20mmol). 
The mixture was stirred at room temperature under nitrogen for 
48h, then concentrated, diluted with water (40mL) and extracted 
with chloroform (40mL). The organic layer was dried, filtered 
and  the  filtrate  concentrated  to  afford  9  as  a  white  solid  (3g, 
97%). 
1
H NMR (300 MHz, CHLOROFORM-d)  8.54 (d, J = 2.0 
Hz, 1H), 8.46 (dd, J = 4.8, 1.4 Hz, 1H), 7.60 - 7.76 (m, 1H), 7.21 
- 7.36 (m, 5H), 5.85 (d, J = 2.3 Hz, 1H), 3.27 (br. s., 1H). 
Preparation  of  chloro  diarylmethyl  intermediates  (7)  from 
diarylmethanol intermediates (6). 
3-[Chloro(4-chlorophenyl)methyl]pyridine (10). A mixture 
of 9 (2.5g, 11mmol), thionyl chloride (5.2g, 44mmol) and toluene 
or dichloromethane (10mL) was stirred at room temperature for 2 
h  with  a  drying  tube  or  heated  under  reflux  overnight.  On 
cooling,  the  mixture  was  concentrated  and  azeotroped  with 
toluene (2x10mL) to afford 10 as a white solid (2.5g, 94%). 
1
H 
NMR (300 MHz, CHLOROFORM-d)  8.63 (d, J = 2.0 Hz, 1H), 
8.57 (dd, J = 4.7, 1.3 Hz, 1H), 7.69 - 7.76 (m, 1H), 7.24 - 7.39 
(m, 5H), 6.11 (s, 1H). 
Preparation of diarylmethylpiperazine intermediates (4 and 
5) from chloro diarylmethyl intermediates (7). 
1-[(4-Chlorophenyl)(pyridin-3-yl)methyl]piperazine  (12). 
To a dry 100mL round bottomed flask fitted with a condenser 
and a stirrer bar was added 10 (5g, 21mmol). This was dissolved 
in  anhydrous  acetonitrile  (40mL)  and  t-butyl  piperazine-1-
carboxylate  (5.9g,  31.5mmol)  was  added  followed  by 
triethylamine  (anhydrous,  5.9mL,  42mmol)  and  a  catalytic 
amount of potassium iodide (dried by heat gun under vacuum). 
The reaction was heated at 80°C for 48 h. The reaction mixture 
was  cooled,  concentrated  and  the  residue  partitioned  between 
dichloromethane  (100mL)  and  a  saturated  aqueous  sodium 
carbonate solution (100mL). The aqueous phase was re-extracted 
with dichloromethane (2x50mL), the organic phases combined, 
dried (sodium sulfate), filtered and concentrated to give a crude 
orange oil. Purification by Flashmaster II chromatography (eluent 
ethylacetate in dichloromethane 0-30%) gave BOC-intermediate 
11  as  a  semi-pure  solid  (16.1g,  80%). 
1
H  NMR  (400  MHz, 
CHLOROFORM-d)  8.62 (br. s., 1H), 8.47 (d, J = 3.9 Hz, 1H), 
7.68 (d, J = 7.8 Hz, 1H), 7.17 - 7.38 (m, 5H), 4.28 (s, 1H), 3.36 - 
3.48  (m,  4H),  2.25  -  2.39  (m,  4H),  1.43  (s,  9H).  11  (3.4g, 
8.8mmol)  was  dissolved  in  dichloromethane  (40mL)  and 
methanol (10 drops) was added. The mixture was cooled to 0°C 
and trifluoroacetic acid (6.5mL, 87.7mmol) was added drop wise. 
The mixture was stirred for 1 h at 0
oC, allowed to come to room 
temperature  overnight,  concentrated  and  azeotroped  with 
dichloromethane  to  give  12  (3.7g)  as  the  crude  trifluoroacetic 
acid salt which was used without further purification. 
1
H NMR 
(400 MHz, DMSO-d6)  8.87 (br. s., 1H), 8.64 - 8.77 (m, 2H), 
8.32 (d, J = 7.8 Hz, 1H), 7.81 (dd, J = 7.6, 5.7 Hz, 1H), 7.39 -   
7.48 (m, 4H), 4.86 (s, 1H), 3.13 (br. s., 4H), 4 protons obscured 
by DMSO peak. 
Preparation of diarylmethylpiperazine analogue libraries (3) 
from diarylmethylpiperazine intermediates (5). Method A. 
Amides  from  acid  chlorides.  1-{4-[(4-
Chlorophenyl)(pyridin-3-yl)methyl]piperazin-1-yl}ethan-1-
one (24). 12 (3.7g) was dissolved in anhydrous dichloromethane 
(30mL)  and  the  solution  cooled  to  0°C.  Triethylamine  (5mL, 
36mmol) was added drop wise with stirring. A further 5mL of 
triethylamine  was  added,  followed  by  drop  wise  addition  of 
acetyl chloride (1.0mL, 14.4mmol) and the mixture allowed to 
stir for 45 min, poured onto aqueous sodium carbonate solution 
(20mL) and extracted with chloroform (3x40mL).  The organic 
phases  were  combined,  dried  (sodium  sulfate),  filtered  and 
concentrated  to  give  a  dark  orange  oil  which  was  purified  by 
Flashmaster II chromatography (eluent chloroform in methanol) 
to give 24 (485mg, 17%) as a hygroscopic colourless solid. 
1
H 
NMR (300 MHz, CHLOROFORM-d)  8.64 (br. s., 1H), 8.49 (d, 
J = 2.4 Hz, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.19 - 7.40 (m, 5H), 
4.30  (s,  1H),  3.62  (apparent  triplet,  J  =  4.9  Hz,  2H),  3.47 
(apparent triplet, J = 4.9 Hz, 2H), 2.28 - 2.48 (m, 4H), 2.06 (s, 
3H); HPLC 96.1% at 230nm; GCMS m/z = 329. 
Sulfonamides  from  sulfonyl  chlorides.  1-
(Benzenesulfonyl)-4-[(4-chlorophenyl)(pyridin-3-
yl)methyl]piperazine  (29).  12  (250mg,  0.24mmol)  was 
dissolved in dichloromethane (2.5mL) under an atmosphere of 
nitrogen and benzenesulfonyl chloride (0.46mL, 2eq) was added 
and the mixture cooled to 0°C. Triethylamine (0.6mL) was added 
and the mixture stirred for 2 hours then allowed to warm to room 
temperature, poured onto a saturated aqueous sodium carbonate 
solution (20mL) and extracted with dichloromethane (3x15mL). 
The organic phases were combined, dried (magnesium sulfate), 
filtered,  concentrated  and  purified  by  Flashmaster  II 
chromatography (eluent ethylacetate in dichloromethane) to give 
29 as an off-white powder (86mg, 83%). 
1
H NMR (300 MHz, 
CHLOROFORM-d)  8.57 (br. s., 1H), 8.45 (br. s., 1H), 7.74 - 
7.78 (m, 2H), 7.54 - 7.68 (m, 4H), 7.24 – 7.26 (m, 4H) 7.16 - 
7.22 (m, 1H), 4.28 (s, 1H) 3.02-3.05 (m, 4H), 2.44-2.48 (m, 4H); 
HPLC >99% at 230nm; LCMS [M+H]+=428.2. 
Carbonates  from  chloroformates.  Phenyl  4-[(4-
chlorophenyl)(pyridin-3-yl)methyl]piperazine-1-carboxylate 
(46)  A  solution  of  12  (0.3g)  in  dichloromethane  (3mL)  was 
cooled to 0°C and triethylamine (1.5mL) was added, followed by 
phenyl  chloroformate  (0.07mL,  0.58mmol).  The  mixture  was 
allowed to warm to room temperature overnight, then 10mL of a 
saturated  solution  of  ammonium  chloride  and  10mL  of 
dichloromethane were added. The organic phase was separated 
and  the  aqueous  phase  re-extracted  with  dichloromethane 
(2x10mL).  The  organic  phases  were  combined,  dried 
(magnesium  sulfate)  filtered  and  concentrated.  The  crude 
material was purified by Flashmaster II chromatography (eluent 
ethyl acetate in hexanes) to give 46 (66mg, 56%) as an off-white 
solid. 
1
H  NMR  (400  MHz,  CHLOROFORM-d)    8.66  (br. s., 
1H), 8.50 (br. s., 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.23 - 7.40 (m, 
7H), 7.20 (d, J = 7.0 Hz, 1H), 7.09 (d, J = 8.2 Hz, 2H), 4.34 (s, 
1H), 3.50 - 3.79 (m, 4H), 2.34 - 2.55 (m, 4H); HPLC 96.9% at 
230 nm; LCMS [M+H]+=408.1. 
Carbamates  from  isocyanates.  4-[(4-
Chlorophenyl)(pyridin-3-yl)methyl]-N-phenylpiperazine-1-
carboxamide  (47).  12  (0.3g,  0.29mmol)  was  dissolved  in 
dichloromethane  (3.0mL)  and  the  solution  was  cooled  to  0°C. 
Triethylamine  (2.0mL)  was  added,  followed  by  phenyl 
isocyanate (52mg, 0.44mmol) and the mixture stirred for 30 min, 
poured into a saturated solution of sodium chloride (20mL) and 
extracted with dichloromethane (2x10mL).  The organic phases 
were  combined,  dried  (magnesium  sulfate)    filtered  and 
concentrated. The crude material was purified by Flashmaster II 
chromatography  (eluent  ethyl  acetate  in  hexanes)  to  give  47 
(83mg, 70%) as a white solid. 
1
H NMR (400 MHz, DMSO-d6)  
8.63 (s, 1H), 8.40 - 8.52 (m, 2H), 7.81 (d, J = 7.8 Hz, 1H), 7.48 
(d, J = 8.6 Hz, 2H), 7.39 - 7.44 (m, 3H), 7.36 (dd, J = 7.6, 4.9 Hz, 
1H), 7.21 (t, J = 7.8 Hz, 2H), 6.92 (t, J = 7.2 Hz, 1H), 4.54 (s, 
1H), 3.42 - 3.52 (m, 4H), 2.23 - 2.38 (m, 4H); HPLC >99% at 
230 nm; LCMS [M+H]+=407.3. 
Aryl  derivatives.  1-[(4-Chlorophenyl)(pyridin-3-
yl)methyl]-4-phenylpiperazine  (62).  A  mixture  of  10  (0.20g, 
0.7mmol), N,N-dimethylformamide (2mL), potassium carbonate 
(0.5g, 2.1mmol) and 1-phenylpiperazine (0.57g, 3.5mmol) was 
heated at 150˚C for 30 min in a microwave. The mixture was 
diluted  with  water  (40mL)  and  extracted  into  ethyl  acetate 
(40mL).  The  organic  layer  was  separated,  washed  with  water 
(40mL), dried, and concentrated. The crude residue was purified 
by Flashmaster II chromatography to give 62 (60mg, 24%) as a 
clear oil. 
1H NMR (300 MHz, CHLOROFORM-d)  8.61 - 8.75 
(m, 1H), 8.42 - 8.56 (m, 1H), 7.68 - 7.85 (m, 1H), 7.20 - 7.42 (m, 
7H), 6.76 - 7.00 (m, 3H), 4.34 (s, 1H), 3.17 - 3.28 (m, 4H), 2.47 - 
2.67 (m, 4H); HPLC >99% at 230nm; GCMS m/z=363. 
Preparation  of  1-[(4-Chloro-2-fluorophenyl)(pyridin-3-
yl)methyl]-4-methanesulfonylpiperazine  (37).  
(4-Chloro-2-fluorophenyl)(pyridin-3-yl)methanol  (67).  To  a 
solution  of  (4-chloro-2-fluorochlorophenyl)(pyridin-3-
yl)methanone (15.6g, 66.2mmol) in methanol (400mL) cooled to 
0
oC  was  slowly  added  sodium  borohydride  (4.5g,  119mmol) 
portion wise. The mixture was stirred at room temperature under 
nitrogen for 24 h, then diluted with water (400mL) and extracted 
into dichloromethane (4x300mL). The organic layer was dried, 
filtered  and    concentrated.  Purification  by  silica  plug  (eluent 
dichloromethane then ethyl acetate) gave 67 as a white powder 
(11.3g,  72%).  1H  NMR  (300  MHz,  CHLOROFORM-d) 
d, J = 2.1 Hz, 1H), 8.48 (dd, J = 4.8, 1.8 Hz, 1H), 7.71- 
7.67 (m, 1H), 7.50 (t, J = 8.1 Hz, 1H), 7.29 – 7.25 ( m, 1H), 7.20- 
7.17 (m, 1H), 7.07 (dd, J = 9.9, 1.8 Hz, 1H), 6.13 (d, J = 3.4 Hz, 
1H),  3.05  (d,  J  =  3.4Hz,  1H);  HPLC    >99%  @230nm.  3-
[Chloro(4-chloro-2-fluorophenyl)methyl]pyridine  (68).  A 
solution of 67 (11.3g, 47.5mmol) in dichloromethane (140mL) 
was  cooled  to  0
oC  and  thionyl  chloride  (5.86mL,  80.8mmol) 
added.  The  reaction  mixture  was  allowed  to  warm  to  room 
temperature over 2 h. The mixture was concentrated, re-extracted 
into dichloromethane and washed with an aqueous solution of 
sodium carbonate. The aqueous layer was treated with salt and 
re-extracted  with  dichloromethane  (3x100mL).  The  organic 
layers  were  combined,  dried  (magnesium  sulfate),  filtered  and 
concentrated to give 68  as a crude light brown oil (11.2g, 93%). 
1H NMR (300 MHz, CHLOROFORM-d) sd, 
J = 3.6, 1H), 7.78-7.74 (m, 1H), 7.49 (t, J = 8.4 Hz, 1H), 7.32 
(dd, J = 8.1, 4.8 Hz, 1H), 7.22 – 7.18 (m, 1H), 7.12 (dd, J = 8.1, 
1.8  Hz,  1H),  6.37  (s,  1H).  1-[(4-Chloro-2-
fluorophenyl)(pyridin-3-yl)methyl]piperazine (69). 68 (11.2g, 
43.7mmol) was dissolved in anhydrous acetonitrile (100mL) and 
t-butyl  piperazine-1-carboxylate  (24.4g,  0.13mmol)  was  added 
followed by triethylamine (anhydrous, 12.2mL, 87.4mmol) and a 
catalytic amount of potassium iodide (dried by heat gun under 
vacuum). The reaction was heated at 80°C for 48 h (an additional 
12mL  triethylamine  and  5g of  t-butyl  piperazine-1-carboxylate   
were  added  after  24h).  The  reaction  mixture  was  cooled, 
concentrated  and  the  residue  partitioned  between 
dichloromethane  (100mL)  and  a  saturated  solution  of  sodium 
carbonate  (100mL).  The  aqueous  phase  was  re-extracted  with 
dichloromethane (3x100mL), the organic phases combined, dried 
(sodium sulfate), filtered and concentrated to give a crude off-
white solid (16.3g, 92%). The crude material (4g, 9.85mmol) was 
dissolved in dichloromethane (40mL) and methanol (1mL) was 
added. The mixture was cooled to 0°C and trifluoroacetic acid 
(10mL, 135mmol) was added drop wise. The mixture was stirred 
for 4 days, concentrated and azeotroped with dichloromethane to 
give 69 (8.5g) as the crude trifluoroacetic acid salt as an orange 
oil which was used without further purification. 
1H NMR (200 
MHz, CHLOROFORM-d) (Free base)  8.64 (s, 1H), 8.42 - 8.51 
(m, 1H), 7.69 (br. d., J = 7.7 Hz, 1H), 7.52 (t, J = 8.1 Hz, 1H), 
7.17 - 7.29 (m, 1H), 7.09 - 7.17 (m, 1H), 7.03 (dd, J = 1.8, 9.9 
Hz, 1H), 4.68 (s, 1H), 2.84 - 3.03 (m, 4H), 2.32 - 2.52 (m, 4H). 
1-[(4-Chloro-2-fluorophenyl)(pyridin-3-yl)methyl]-4-
methanesulfonylpiperazine  (37).  69  (5g,  5.8mmol)  was 
dissolved  in  a  solution  of  dichloromethane  (40mL)  containing 
triethylamine  (5mL)  at  0
oC. Methanesulfonyl  chloride  (0.9mL, 
11.6mmol) was added drop wise and the mixture stirred for 2 h 
then  allowed  to  warm  to  room  temperature,  poured  onto  a 
saturated solution of ammonium chloride (20mL) and extracted 
with  dichloromethane  (3x30mL).  The  organic  phases  were 
combined, dried (magnesium sulfate), filtered, concentrated and 
purified by preparative HPLC (eluent 30% acetonitile in water) 
to give 37 as an off-white solid (690mg, 31%). 
1H NMR (300 
MHz, CHLOROFORM-d)  8.64 - 8.68 (m, 1H), 8.48 - 8.54 (m, 
1H), 7.63 - 7.72 (m, 1H), 7.47 (t, J = 8.0 Hz, 1H),7.21 - 7.25 (m, 
1H), 7.11 - 7.18 (m, 1H), 7.02 - 7.10 (m, 1H), 4.76 (s, 1H), 3.27 
(apparent triplet, J = 4.8 Hz, 4H), 2.81 (s, 3H), 2.44 - 2.62 (m, 
4H); HPLC 97.4% at 230nm; LCMS [M+H]
+=384.1. 
5.3. Biological assays. 
General  methods  for  the  in  vitro  T.  cruzi  assay  for 
determination  of  IC50,  in  vitro  assay  for  determination  of 
cytotoxicity,  solubility,  microsomal  stability,  cytochrome  P450 
3A4/5 and in vivo efficacy model of acute T. cruzi infection in 
mice as previously described.
25 
Acknowledgments 
DNDi is grateful to its donors, public and private, who have 
provided funding to DNDi since its inception in 2003. With the 
support of these donors, DNDi is well on its way to achieving the 
objectives of building a robust pipeline and delivering 6-8 new 
treatments by 2014. A full list of DNDi‟s donors can be found at 
http://www.dndi.org/index.php/donors.htmL?ids=8. For the work 
described in this paper, DNDi received financial support from the 
following  donors:  Department  for  International  Development 
(DFID)  /  UNITED  KINGDOM,  GiZ  on  behalf  of  the 
Government of the Federal Republic of Germany / GERMANY, 
Ministry of Foreign and European Affairs (MAEE) / FRANCE, 
Spanish  Agency  for  International  Development  Cooperation 
(AECID)  /  SPAIN,  Swiss  Agency  for  Development  and 
Cooperation  (SDC)  /  SWITZERLAND,  Medecins  Sans 
Frontieres (Doctors without Borders) / INTERNATIONAL and a 
Swiss foundation. The donors had no role in study design, data 
collection and analysis, decision to publish, or preparation of the 
manuscript. 
The authors thank Harriet Newson and Sarah Keatley for help 
in  preparing  the  manuscript  and  Jason  Chaplin  and  Michael 
Abbott for additional chemistry support. 
References and notes 
1.  Nature Outlook 2010, 24th June. 
2.  Hotez, P. J.; Dumonteil, E.; Woc-Colburn, L.; Serpa, J. A.; Bezek, 
S.; Edwards, M. S.; Hallmark, C. J.; Musselwhite, L. W.; Flink, B. 
J.; Bottazzi, M. E. PLoS Negl Trop Dis 2012, 6, e1498. 
3.  Andrade, L. O.; Andrews, N. W. Nature Rev. Microbiol. 2005, 3, 
819. 
4.  Cencig, S.; Coltel, N.; Truyens, C.; Carlier, Y. PLoS Negl Trop 
Dis 2011, 5, e1216. 
5.  Bern, C. N. Engl. J. Med. 2011, 364, 2527. 
6.  Martins-Melo, F.; Alencar, C. H.; Ramos, A. N., Jr.; Heukelbach, 
J. PLoS Negl Trop Dis 2012, 6, e1508. 
7.  Moolani, Y.; Bukhman, G.; Hotez, P. J. PLoS Negl Trop Dis 2012, 
6, e1499. 
8.  Zingales, B.; Miles, M. A.; Campbell, D. A.; Tibayrenc, M.; 
Macedo, A. M.; Teixeira, M. M. G.; Schijman, A. G.; Llewellyn, 
M. S.; Lages-Silva, E.; Machado, C. R.; Andrade, S. G.; Sturm, N. 
R. Infection, Genetics and Evolution 2012, 12, 240. 
9.  Lepesheva, G. I.; Hargrove, T. Y.; Kleshchenko, Y.; Nes, D. W.; 
Villalta, F.; Waterman, M. R. Lipids 2008, 43, 1117. 
10.   Lepesheva, G. I.; Waterman, M. R. Biochim. Biophys Acta. 2007, 
1770, 467. 
11.  Urbina, J. A. Curr. Pharm. Des. 2002, 8, 287. 
12.  Urbina, J. A.; Docampo, R. TRENDS in Parasitol. 2003, 19, 495. 
13.  Urbina, J. A.; Payares, G.; Sanoja, C.; Lira, R.; Romanha, A. J. In. 
J. Antimicrob. Agents 2003, 21, 27. 
14.  Diniz, L.; Caldas, I. S.; Guedes, P. M. d. M.; Crepalde, G.; de 
Lana, M.; Carneiro, C. M.; Talvani, A.; Urbina, J. A.; Bahia, M. 
T. Antimicrob. Agents Chemother. 2010, 54, 2979. 
15.  Buckner, F. S.; Bahia, M. T.; Suryadevara, P. K.; White, K. L.; 
Shackleford, D. M.; Chennamaneni, N. K.; Hulverson, M. A.; 
Laydbak, J. U.; Chatelain, E.; Scandale, I.; Verlinde, C. L. M. J.; 
Charman, S. A.; Lepesheva, G. I.; Gelb, M. H. Antimicrob. Agents 
Chemother. 2012, 56, 4914. 
16.  Kraus, J. M.; Tatipaka, H. B.; McGuffin, S. A.; Chennamaneni, N. 
K.; Karimi, M.; Arif, J.; Verlinde, C. L. M. J.; Buckner, F. S.; 
Gelb, M. H. J. Med. Chem. 2010, 53, 3887.   
17.  Kraus, J. M.; Verlinde, C. L. M. J.; Karimi, M.; Lepesheva, G. I.; 
Gelb, M. H.; Buckner, F. S. J. Med. Chem. 2009, 52, 1639. 
18.  Hucke, O.; Gelb, M. H.; Verlinde, C. L. M. J.; Buckner, F. S. J. 
Med. Chem. 2005, 48, 5415. 
19.  Suryadevara, P. K.; Olepu, S.; Lockman, J. W.; Ohkanda, J.; 
Karimi, M.; Verlinde, C. L. M. J.; Kraus, J. M.; Schoepe, J.; Van 
Voorhis, W. C.; Hamilton, A. D.; Buckner, F. S.; Gelb, M. H. J. 
Med. Chem. 2009, 52, 3703. 
20.  Doyle, P. S.; Chen, C.; Johnston, J. B.; Hopkins, S. D.; Leung, S. 
S. F.; Jacobson, M. P.; Engel, J. C.; McKerrow, J. H.; Podust, L. 
M. Antimicrob. Agents Chemother. 2010, 54, 2480. 
21.   Konkle, M. E.; Hargrove, T. Y.; Kleshchenko, Y. Y.; von Kries, 
J. P.; Ridenour, W.; Uddin, J. M.; Caprioli, R. M.; Marnett, L. J.; 
Nes, W. D.; Villalta, F.; Waterman, M. R.; Lepesheva, G. I. J. 
Med. Chem. 2009, 52, 2846. 
22.  Gunatilleke, S. S.; Calvet, C. M.; Johnston, J. B.; Chen, C.; 
Erenburg, G.; Gut, J.; Engel, J. C.; Ang, K. K. H.; Mulvaney, J.; 
Chen, S.; Arkin, M. R.; McKerrow, J. H.; Podust, L. M. PLoS 
Negl Trop Dis 2012, 6, e1736. 
23.  Lepesheva, G. I.; Hargrove, T. Y.; Anderson, S.; Kleshchenko, Y.; 
Furtak, V.; Wawrzak, Z.; Villalta, F.; Waterman, M. R. J. Biol. 
Chem. 2010, 33, 25582. 
24.  Chen, C.; Leung, S. S. F.; Guilbert, C.; Jacobson, M. P.; 
McKerrow, J. H.; Podust, L. M. PLoS Negl Trop Dis 2010, 4, 
e651. 
25.  Keenan, M.; Abbott, M. J.; Alexander, P. W.; Armstrong, T.; Best, 
W. M.; Berven, B.; Botero, A.; Chaplin, J. H.; Charman, S. A.; 
Chatelain, E.; von Geldern, T. W.; Kerfoot, M.; Khong, A.; 
Nguyen, T.; McManus, J. D.; Morizzi, J.; Ryan, E.; Scandale, I.; 
Thompson, R. A.; Wang, S. Z.; White, K. L. J. Med. Chem. 2012, 
55, 4189. 
26.  Buckner, F. S.; Verlinde, C. L.; La Flamme, A. C.; Van Voorhis, 
W. C. Antimicrob. Agents Chemother. 1996, 40, 2592.   
27.  www. FRAC. Info 
28.  Cronin, S.; Chandrasekar, P. H. J. Antimicrob. Chemother. 2010, 
65, 410–416 
Supplementary Material 
Additional  synthetic  methods  for  the  preparation  of 
intermediates to final compounds, spectroscopic/analytical data 
and oral exposure profiles for 24 and 37 is available. 
 
 
   
Figure 1. Fenarimol (1), 2 and proposed scaffold (3) 
Figure 2. Scope of SAR investigation 
Figure 3. Efficacy of compounds on blood parasitemia in vivo. 
Animals were administered A) 24, B) 37 or C) posaconazole once 
daily for 5 days at different concentrations. Parasitemia per ml blood 
was evaluated relative to vehicle-treated animals. t indicates animal 
death due to parasite burden/morbidity. Error bars represent SEM. 
Figure  4.  Survival  following  compound  treatment.  Animals 
were administered A) 24 or B) 37 once daily for 5 days at different 
concentrations.  Percent  survival  relative  to  treatment  with 
posaconazole (100mg/kg) or vehicle only is shown. 
Scheme 1 
Scheme 2.  1. NaBH4, MeOH, RT, 48h, (97%); 2. 9, SOCl2, Tol, 
reflux, 18h, (94%); 3. 10, BOC-piperazine, NEt3, KI, AcCN, 80
oC, 
48h, (80%). 4. 11, TFA, DCM, MeOH, RT, 18h, (quant.). 5.a) 12, 
CH3COCl, DCM, Et3N, 0
oC-RT, 1h, (17%); b) 12, PhSO2Cl, DCM, 
Et3N, 0
oC-RT, 2h (83%) ; c) 12, PhOCOCl, DCM, Et3N, 0
oC-RT, 
12h (56%); d) 12, PhN=C=O, DCM, Et3N, 0
oC-RT, 45mins, (70%). 
Scheme  3.  10,  1-phenylpiperazine,  DMF,  K2CO3,  150
oC, 
microwave, 30min (24%) 
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